The potential use of a third generation (CD28 and 4-1BB co-stimulatory domains) CD7-specific uCAR for the treatment of r/r T-ALL and non-Hodgkin’s T-cell lymphoma, was described [104]. This evidence concerns the gene CD28 and T-cell non-Hodgkin lymphoma.